Format

Send to

Choose Destination
World J Biol Psychiatry. 2017 Aug;18(5):330-356. doi: 10.1080/15622975.2016.1224929. Epub 2016 Oct 26.

Consensus paper of the WFSBP Task Force on Biological Markers: Criteria for biomarkers and endophenotypes of schizophrenia, part III: Molecular mechanisms.

Author information

1
a Department of Psychiatry and Psychotherapy , LMU Munich , Germany.
2
b Laboratory of Neuroscience (LIM27) , Institute of Psychiatry, University of Sao Paulo , Sao Paulo , Brazil.
3
c Laboratory of Neuroproteomics, Department of Biochemistry , Institute of Biology University of Campinas (UNICAMP), Campinas , SP , Brazil.
4
d Division of Psychiatric Epigenomics, Departments of Psychiatry and Neuroscience , Mount Sinai School of Medicine , New York , USA.
5
e Clinical Neuroscience , Max Planck Institute of Experimental Medicine, DFG Centre for Nanoscale Microscopy & Molecular Physiology of the Brain , Göttingen , Germany.
6
f Research Group for Epigenetics in Neurodegenerative Diseases , German Centre for Neurodegenerative Diseases (DZNE), Göttingen , Germany.
7
g Department of Psychiatry and Psychotherapy , University Medical Centre Göttingen , Germany.
8
h Neurosciences , Huntington Medical Research Institutes , Pasadena , CA , USA.
9
i Department of Psychiatry and Psychotherapy , University of Würzburg , Germany.
10
j Centre for Mental Health, Department of Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy , University of Würzburg , Germany.
11
k Department of Child and Adolescent Psychiatry and Psychotherapy , Psychiatric Hospital, University of Zürich , Switzerland.
12
l Neuroscience Centre Zurich , University of Zurich and the ETH Zurich , Switzerland.
13
m Zurich Centre for Integrative Human Physiology , University of Zurich , Switzerland.
14
n Division of Clinical Neuroscience , Chiba University Centre for Forensic Mental Health , Chiba , Japan.
15
o Department of Psychiatry , Korea University, College of Medicine , Republic of Korea.
16
p Department of Psychiatry and Psychotherapy , Friedrich-Alexander-University Erlangen-Nuremberg , Erlangen , Germany.
17
q Institute of Neuropathology, LMU Munich , Germany.
18
r Department of Psychiatry, Molecular and Behavioural Neurobiology , LMU Munich , Germany.
19
s Research Group Gene Expression , Max Planck Institute of Experimental Medicine , Göttingen , Germany.
20
t Institute for Laboratory Medicine, LMU Munich , Germany.
21
u Department of Psychiatry , University of Magdeburg , Magdeburg , Germany.
22
v Department of Psychiatry , University Hospital Cochin (site Tarnier), University of Paris-Descartes, INSERM U 894 Centre Psychiatry and Neurosciences , Paris , France.
23
w Center of Psychic Health; Department of Psychiatry, Psychosomatics and Psychotherapy , University Hospital of Würzburg , Germany.

Abstract

OBJECTIVES:

Despite progress in identifying molecular pathophysiological processes in schizophrenia, valid biomarkers are lacking for both the disease and treatment response.

METHODS:

This comprehensive review summarises recent efforts to identify molecular mechanisms on the level of protein and gene expression and epigenetics, including DNA methylation, histone modifications and micro RNA expression. Furthermore, it summarises recent findings of alterations in lipid mediators and highlights inflammatory processes. The potential that this research will identify biomarkers of schizophrenia is discussed.

RESULTS:

Recent studies have not identified clear biomarkers for schizophrenia. Although several molecular pathways have emerged as potential candidates for future research, a complete understanding of these metabolic pathways is required to reveal better treatment modalities for this disabling condition.

CONCLUSIONS:

Large longitudinal cohort studies are essential that pair a thorough phenotypic and clinical evaluation for example with gene expression and proteome analysis in blood at multiple time points. This approach might identify biomarkers that allow patients to be stratified according to treatment response and ideally also allow treatment response to be predicted. Improved knowledge of molecular pathways and epigenetic mechanisms, including their potential association with environmental influences, will facilitate the discovery of biomarkers that could ultimately be effective tools in clinical practice.

KEYWORDS:

Schizophrenia; biomarkers; epigenetics; lipids; proteomics

PMID:
27782767
DOI:
10.1080/15622975.2016.1224929
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Taylor & Francis
Loading ...
Support Center